In an obese smoker with episodic tachycardia and isolated thrombocytosis (platelet count 561 ×10⁹/L) and otherwise normal complete blood count, what is the appropriate evaluation and management?

Evaluation and Management of Isolated Thrombocytosis in an Obese Smoker with Episodic Tachycardia

This patient requires workup to distinguish reactive (secondary) thrombocytosis from essential thrombocythemia, with the episodic tachycardia evaluated separately as it is unlikely related to the platelet count of 561.

Initial Assessment

The platelet count of 561 × 10⁹/L meets the definition of thrombocytosis (>450 × 10⁹/L) 1. Given the patient's obesity and smoking status, reactive thrombocytosis is the most likely diagnosis, as secondary causes account for approximately 88% of all thrombocytosis cases 2.

Key Distinguishing Features

Reactive thrombocytosis is suggested by:

• Obesity (associated with elevated platelet counts in females with chronic inflammation) 3
• Smoking status (though smoking itself doesn't significantly alter platelet counts) 4
• Platelet count <800 × 10⁹/L (extreme thrombocytosis more typical of primary causes) 5

Essential thrombocythemia would be suggested by:

• Platelet count persistently >800 × 10⁹/L
• Duration >1 month without identified cause
• Symptoms of microvascular disease (headaches, paresthesias, erythromelalgia)
• Splenomegaly 1

Diagnostic Algorithm

Step 1: Confirm True Thrombocytosis

• Repeat CBC with differential and peripheral blood smear to exclude pseudothrombocytosis and assess other cell lines 1
• Review any prior platelet counts to determine if acute or chronic 6

Step 2: Identify Secondary Causes

Order the following tests based on the clinical context 1, 5:

• C-reactive protein (CRP) - elevated in inflammatory/infectious causes
• Ferritin and iron studies - iron deficiency is a common cause
• Comprehensive metabolic panel - assess for renal/hepatic disease
• Chest imaging if indicated - evaluate for occult infection or malignancy

Common secondary causes to consider:

• Tissue damage/inflammation (42% of cases) 2
• Infection (24% of cases) - particularly relevant with fever, tachycardia, leukocytosis 5
• Malignancy (13% of cases) 2
• Chronic inflammation (10% of cases) 2

Step 3: If No Secondary Cause Identified

Proceed with myeloproliferative neoplasm workup 1:

1. JAK2 V617F mutation testing (first-line)
2. If JAK2 negative: CALR and MPL mutation testing
3. Bone marrow biopsy to confirm essential thrombocythemia

Management Based on Diagnosis

If Reactive Thrombocytosis:

• Treat the underlying condition - the platelet count should normalize with resolution 1
• No antiplatelet therapy needed unless other cardiovascular risk factors warrant it
• Secondary thrombocytosis carries minimal thrombotic risk unless additional risk factors present 2

If Essential Thrombocythemia Confirmed:

Calculate the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET) 1:

• Age >60 years (1 point)
• Cardiovascular risk factors (1 point) - this patient has obesity and smoking
• Previous thrombosis (2 points)
• JAK2V617F mutation (2 points)

Risk stratification:

• Low risk (0-1 points): Observation, address cardiovascular risk factors
• Intermediate risk (2 points): Low-dose aspirin 7
• High risk (≥3 points): Hydroxyurea (first-line cytoreductive therapy) plus low-dose aspirin 7, 1

Critical management points:

• Address cardiovascular risk factors aggressively (smoking cessation, weight management) 7
• Hydroxyurea is first-line for cytoreduction in high-risk patients 7
• Platelet count >1,500 × 10⁹/L increases bleeding risk and warrants cytoreduction 7

Addressing the Episodic Tachycardia

The tachycardia is unlikely related to the thrombocytosis. Evaluate separately:

Assess for:

• Sinus tachycardia triggers: hyperthyroidism, dehydration, anemia, fever 8
• Supraventricular tachycardia if rate >150 bpm 8
• Atrial fibrillation (particularly relevant given obesity) 8

Initial workup:

• ECG during symptomatic episode
• Thyroid function tests
• Echocardiogram if structural heart disease suspected
• Consider ambulatory monitoring if episodes are frequent

Management depends on rhythm identified - if sinus tachycardia at rates <150 bpm, focus on treating underlying physiologic stress rather than the tachycardia itself 8.

Critical Pitfalls to Avoid

• Do not assume thrombocytosis causes tachycardia - these are separate issues requiring independent evaluation
• Do not start antiplatelet therapy for reactive thrombocytosis alone - it provides no benefit and increases bleeding risk 2
• Do not delay infection workup - infection is a common cause of thrombocytosis and may explain both the elevated platelets and tachycardia 5
• Do not overlook cardiovascular risk modification - obesity and smoking are modifiable risk factors that impact both thrombotic risk and cardiovascular health 7